ARTV Stock — Artiva Biotherapeutics Inc.: Cash, EV, Pipeline

Share price

$8.61

Market cap

$420.9M

Cash

$349.4M

Enterprise value

$71.5M

Balance sheet

Cash	$349.4M
Debt	$0.0M
Net cash	$349.4M
Enterprise value	$71.5M
Basic shares	39.4M shares
Fully diluted shares	57.1M shares
Fully diluted market cap	$491.4M
Cash per share	$8.87

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading ARTV daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Aug 12 - Sep 23	AB-101	Phase 1	Rheumatoid Arthritis; Pemphigus Vulgaris; Granulomatosis With Polyangiitis	—
Sep 12 - Oct 24	AB-101	Phase 1	Lupus Nephritis - WHO Class III; Lupus Nephritis - WHO Class IV; Refractory Systemic Lupus Erythematosus	—
Sep 12 - Oct 24	GCC2005	Phase 1	Lymphoma, T-Cell	—
Feb 12 - Mar 25	Allogeneic NK Cells	Phase 2	Refractory Rheumatoid Arthritis (RA); Idiopathic Inflammatory Myopathies (IIMs); Systemic Sclerosis (SSc)	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

AlloNK

Phase 3 · Active Modality: allogeneic NK cell therapy

Partnerships GC Cell: option/license agreements plus master manufacturing agreement for NK cell therapy platform and core products

Indications

refractory rheumatoid arthritis (with rituximab) (Phase 3)
Sjögren's disease (with rituximab) (Phase 1)
systemic sclerosis (with rituximab) (Phase 1)

Catalysts

— first half of 2026

Status note Off-the-shelf allogeneic NK cell therapy given with rituximab. FDA aligned on a single registrational randomized controlled Phase 3 trial in refractory RA (two doses with rituximab following low-dose conditioning). Phase 1/2 B-NHL trial completed July 2025; long-term follow-up discontinued to focus resources on autoimmune indications.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Allogeneic NK Cells
Lead indication	Refractory Rheumatoid Arthritis (RA)
Lead phase	Phase 2
Active trials	2
Collaborator trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06991114	Phase 2	Recruiting	Sponsor	ARTV	—	Refractory Rheumatoid Arthritis (RA); Idiopathic Inflammatory Myopathies (IIMs); Systemic Sclerosis (SSc)	—
NCT06265220	Phase 1	Active, not recruiting	Sponsor	ARTV	—	Lupus Nephritis - WHO Class III; Lupus Nephritis - WHO Class IV; Refractory Systemic Lupus Erythematosus	—
NCT06581562	Phase 1	Recruiting	Collaborator	IRIS Research and Development, LLC	—	Rheumatoid Arthritis; Pemphigus Vulgaris; Granulomatosis With Polyangiitis	—
NCT06699771	Phase 1	Recruiting	Collaborator	GC Cell Corporation	—	Lymphoma, T-Cell	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 2 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 4 active trials for Artiva Biotherapeutics, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	118,624	+118,624	0.05%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

ARTV — Artiva Biotherapeutics Inc.